SI1272195T1 - Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk - Google Patents

Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk

Info

Publication number
SI1272195T1
SI1272195T1 SI200130435T SI200130435T SI1272195T1 SI 1272195 T1 SI1272195 T1 SI 1272195T1 SI 200130435 T SI200130435 T SI 200130435T SI 200130435 T SI200130435 T SI 200130435T SI 1272195 T1 SI1272195 T1 SI 1272195T1
Authority
SI
Slovenia
Prior art keywords
fulvestrant
treatment
breast cancer
resistant breast
resistant
Prior art date
Application number
SI200130435T
Other languages
English (en)
Inventor
Beat Thurlimann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0008172.9A external-priority patent/GB0008172D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SI1272195T1 publication Critical patent/SI1272195T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
SI200130435T 2000-04-05 2001-04-02 Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk SI1272195T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0008172.9A GB0008172D0 (en) 2000-04-05 2000-04-05 Therapy
EP01917289A EP1272195B1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer
PCT/GB2001/001500 WO2001074366A1 (en) 2000-04-05 2001-04-02 Use of fulvestrant in the treatment of resistant breast cancer

Publications (1)

Publication Number Publication Date
SI1272195T1 true SI1272195T1 (sl) 2006-02-28

Family

ID=35034671

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130435T SI1272195T1 (sl) 2000-04-05 2001-04-02 Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk

Country Status (1)

Country Link
SI (1) SI1272195T1 (sl)

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
IL158273A0 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EP1311262A4 (en) COMBINED TREATMENT AGAINST CANCER
AU6147401A (en) Compositions and methods for the treatment of cancer
HUP0200763A2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
HUP0401903A3 (en) Improved use of et-743 in cancer thereapy
HUP0500424A3 (en) Combination therapy for the treatment of cancer
SI1716853T1 (sl) Zdravljenje rakov äśloveĺ kega telesa z uporabo et743
AU2003212634A8 (en) Compounds useful in the treatment of cancer
HUP0300339A3 (en) Use of fulvestrant in the treatment of resistant breast cancer
EE200200479A (et) Eksemestaani kasutamine rinnavähi ravis
GB0001710D0 (en) Therapeutic treatment
EP1420814A4 (en) COMPOSITIONS AND TECHNIQUES FOR THERAPY AND DIAGNOSIS OF BREAST CANCER
PL366066A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
IL161762A0 (en) Estradiol inhibiting agents in breast cancer
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
PL350863A1 (en) Compositions and methods for the treatment and diagnosis of breast cancer
IL145149A0 (en) Radioactive cisplatin in the treatment of cancer
AU2096002A (en) Therapeutic treatment
GB0026015D0 (en) Cancer treatment
IL149281A0 (en) Treatment of cancer
SI1272195T1 (sl) Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk